These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Obesity and the metabolic syndrome in the elderly--a mini-review. Lechleitner M Gerontology; 2008; 54(5):253-9. PubMed ID: 18841025 [TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome: is it a syndrome? Does it matter? Kahn R Circulation; 2007 Apr; 115(13):1806-10; discussion 1811. PubMed ID: 17404171 [No Abstract] [Full Text] [Related]
7. Metabolic domino: new concept in lifestyle medicine. Itoh H Drugs Today (Barc); 2006 Dec; 42 Suppl C():9-16. PubMed ID: 17245476 [TBL] [Abstract][Full Text] [Related]
8. The metabolic syndrome and its cardiovascular manifestations. Sánchez-Torres RJ; Delgado-Osorio H Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068 [TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome, cardiovascular disease and type-2 diabetes. Bano KA; Batool A J Pak Med Assoc; 2007 Oct; 57(10):511-5. PubMed ID: 17990428 [TBL] [Abstract][Full Text] [Related]
10. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Kendall DM; Harmel AP Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Ahmed I; Goldstein BJ Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936 [TBL] [Abstract][Full Text] [Related]
12. Hypertension as part of the metabolic syndrome. Cheung B J Hum Hypertens; 2008 Dec; 22(12):871-4. PubMed ID: 18548089 [TBL] [Abstract][Full Text] [Related]
13. Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Watson KE Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393 [TBL] [Abstract][Full Text] [Related]
14. [Metabolic Syndrome: clinical and pathophysiological basis for a rational therapeutical approach]. Martínez R G; Alonso K R; Novik A V Rev Med Chil; 2009 May; 137(5):685-94. PubMed ID: 19701560 [TBL] [Abstract][Full Text] [Related]
15. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction. Sacks FM Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082 [No Abstract] [Full Text] [Related]
16. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. Mayer-Davis EJ; Ma B; Lawson A; D'Agostino RB; Liese AD; Bell RA; Dabelea D; Dolan L; Pettitt DJ; Rodriguez BL; Williams D; Metab Syndr Relat Disord; 2009 Apr; 7(2):89-95. PubMed ID: 18847385 [TBL] [Abstract][Full Text] [Related]
17. [Questions in diabetology to be elucidated]. Simon K; Dobó E; Szépvölgyi A; Szalczer E; Kazup S; Papp L; Varga E Orv Hetil; 2011 Aug; 152(34):1353-61. PubMed ID: 21835741 [TBL] [Abstract][Full Text] [Related]
18. Clinical implications of the metabolic syndrome. Ceska R Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S2-4. PubMed ID: 17935057 [TBL] [Abstract][Full Text] [Related]
19. Obesity and metabolic syndrome as related to cardiovascular disease. Nikolopoulou A; Kadoglou NP Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):933-9. PubMed ID: 22908926 [TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of the metabolic syndrome: implications for the cardiometabolic risks associated with type 2 diabetes. Leroith D Am J Med Sci; 2012 Jan; 343(1):13-6. PubMed ID: 22205060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]